Evidence map›Paper›PMID 41868180›Full record

ArticleDrug design, development and therapy2026

Investigation of Potent Anti-

Ahmed Sabt, Małgorzata Korycka-Machala, Asmaa F Kassem, Ninh The Son, Nguyen Xuan Ha, Anna Brzostek, Mohamed G Thabit, Malwina Kawka, Bożena Dziadek, Abdelsamed I Elshamy and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Ahmed SabtChemistry of Natural Compounds Department, Pharmaceutical and Drug Industries Research Institute, National Research Centre, Cairo, 12622, Egypt.ORCID 0000-0001-6976-0196
Małgorzata Korycka-MachalaLaboratory of Genetics and Physiology of Mycobacterium, Institute of Medical Biology of the Polish Academy of Sciences, Lodz, Poland.
Asmaa F KassemDepartment of Chemistry, College of Science and Humanities in Al-Kharj, Prince Sattam Bin Abdulaziz University, Al-Kharj, Saudi Arabia.
Ninh The SonInstitute of Chemistry, Vietnam Academy of Science and Technology, Hanoi, 10000, Vietnam.
Nguyen Xuan HaInstitute of Chemistry, Vietnam Academy of Science and Technology, Hanoi, 10000, Vietnam.
Anna BrzostekLaboratory of Genetics and Physiology of Mycobacterium, Institute of Medical Biology of the Polish Academy of Sciences, Lodz, Poland.
Mohamed G ThabitDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Pharos University (PUA), Alexandria, Egypt.
Malwina KawkaDepartment of Molecular Microbiology, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Poland.
Bożena DziadekDepartment of Molecular Microbiology, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Poland.
Abdelsamed I ElshamyChemistry of Natural Compounds Department, Pharmaceutical and Drug Industries Research Institute, National Research Centre, Cairo, 12622, Egypt.
Ahmed M AtwaCollege of Pharmacy, Al-Ayen Iraqi University, AUIQ, An Nasiriyah, Iraq.
Jarosław DziadekLaboratory of Genetics and Physiology of Mycobacterium, Institute of Medical Biology of the Polish Academy of Sciences, Lodz, Poland.ORCID 0000-0003-1427-884X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Tuberculosis is a very complicated disease because of how the TB bacteria behaves in the human body. This makes it hard to diagnose, treat, and control. Because of this, the World Health Organization's latest reports show that there are still very few good treatment options for drug-resistant TB. Methods: A novel series of pyridine-derived compounds were rationally designed and synthesized to evaluate their potential as antitubercular agents. These derivatives were specifically developed to target the enoyl acyl carrier protein reductase (InhA), and molecular docking studies were performed to predict binding modes with InhA. Results: All compounds exhibited notable antitubercular activity, with minimum inhibitory concentrations (MIC) ranging from 0.5 to 2.0 μg mL Discussion: Derivative

Indexed as

Antitubercular AgentsBacterial ProteinsDrug DesignMycobacterium tuberculosisOxidoreductasesPyridinesDose-Response Relationship, DrugEnoyl-(Acyl-Carrier-Protein) Reductase (NADH)HumansMicrobial Sensitivity TestsMolecular Docking SimulationMolecular StructureStructure-Activity RelationshipAntitubercular AgentsBacterial ProteinsEnoyl-(Acyl-Carrier-Protein) Reductase (NADH)InhA protein, MycobacteriumOxidoreductasespyridinePyridinesdocking and molecular dynamicsInhA enzymeMycobacterium tuberculosispyridinethiazole derivatives

Identifiers

PMID41868180
PMCPMC13000758

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.